Mayor & City Council of Baltimore v. AbbVie Inc., No. 20-2402 (7th Cir. 2022)Annotate this Case
The Seventh Circuit affirmed the judgment of the district court dismissing this complaint alleging that certain patents related to the medicine Humira and the settlement of litigation about them violated sections one and two of the Sherman Antitrust Act, 15 U.S.C. 1 & 2, holding that dismissal was proper.
At the end of 2016, the basic U.S. patient for Humira, a monoclonal antibody, expired. AbbVie, Humira's owner, obtained 132 additional patents related to the medicine for issues such as manufacturing or administering the drug, the last of which expires in 2034. Plaintiffs, welfare-benefit plans that paid for Humira on behalf of covered beneficiaries, brought this complaint alleging that AbbVie violated the Sherman Act by obtaining the 132 patents. The district court dismissed the complaint. The Seventh Circuit affirmed, holding that Plaintiffs failed to state a claim under the Sherman Act.
The court issued a subsequent related opinion or order on August 2, 2022.